ArticleFrontiers in oncology2026
Peripheral immune cell profiles and tumor marker expression in high-risk HPV-infected cervical lesions: a comparative study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the levels of peripheral blood immune cells CD4 Methods: A total of 240 female patients with HR-HPV infection treated at Hebei Central Hospital of Petroleum between January 2022 and December 2023 were retrospectively enrolled and categorized into three groups based on histopathological diagnosis: cervical cancer group (n=80), cervical intraepithelial neoplasia (CIN) group (n=80), and chronic cervicitis group (n=80). Peripheral blood mononuclear cells (PBMCs) were isolated, and the percentages of CD4 Result: The cervical cancer group showed significantly lower CD4 Conclusion: Patients with HR-HPV-infected cervical lesions exhibit distinct alterations in peripheral immune cell profiles and tumor marker expression. Assessment of these biomarkers may facilitate the early identification of cervical lesions associated with HR-HPV infection and inform the development of preventive and therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.